Syndax Pharmaceuticals Inc
SNDX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNDX
Syndax Pharmaceuticals Inc (SNDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies, with two FDA-approved medicines—Revuforj (revumenib) and Niktimvo (axatilimab)—and a pipeline of additional candidates.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.73B
Cash Runway
57.0 moLead Asset
Axatilimab (Phase 2)Next Catalyst
Phase3_Topline · Jan 1, 2031Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 11 clinical trials · 2 catalysts · 1 FDA decision for Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc (SNDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies, with two FDA-approved medicines—Revuforj (revumenib) and Niktimvo (axatilimab)—and a pipeline of additional candidates.
- Syndax has two FDA-approved medicines: Revuforj (revumenib) and Niktimvo (axatilimab) [sec_mda · as of 2026-02-26].
- As of 2026-06-30, the company reported cash and equivalents of $336.5M, total revenue of $72.8M, and a net loss of -$49.4M [sec].
- The company has incurred significant operating losses since inception and has not achieved profitability except for 2021 [sec_mda · as of 2026-02-26].
- Syndax is conducting a Phase 3 randomized, double-blind, placebo-controlled study of revumenib in combination with intensive chemotherapy [upcoming catalysts].
- The company faces uncertainty in clinical trial costs, timelines, and outcomes, and cannot estimate the amounts needed to complete development or achieve profitability [sec_mda · as of 2026-08-04].
What works
- Syndax has two FDA-approved products (Revuforj and Niktimvo) generating revenue, with a collaboration partner (Incyte) for axatilimab [sec_mda · as of 2026-02-26].
- The company has a cash position of $336.5M as of 2026-06-30, providing a runway for ongoing operations and clinical trials [sec].
- Syndax is leveraging its management team and scientific collaborators to license, acquire, and develop additional therapeutics [sec_mda · as of 2026-02-26].
What to weigh
- Syndax has incurred significant operating losses since inception and has not achieved profitability except for 2021 [sec_mda · as of 2026-02-26].
- The company faces uncertainty in clinical trial costs, timelines, and outcomes, and cannot estimate the amounts needed to complete development or achieve profitability [sec_mda · as of 2026-08-04].
- Macroeconomic conditions, including inflation, supply chain constraints, and geopolitical tensions, could increase operating costs and negatively affect operations [sec_mda · as of 2026-02-26].
- The company has total debt of $350.0M as of 2026-06-30, which may impose financial obligations [sec].
From the filings
Quoted directly from source documents.
Syndax has two FDA-approved medicines from its pipeline.
“first two FDA approved medicines to emerge from our pipeline.”
SEC MD&A · February 26, 2026
The company has incurred significant operating losses since inception.
“We have incurred significant operating losses since our inception.”
SEC MD&A · February 26, 2026
Clinical trial costs and outcomes are uncertain.
“in clinical trials is costly, and the timing, progress and outcomes in these trials is uncertain.”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2031-01-01 · Phase3_Topline · revumenib — Phase 3 Topline — A Phase 3, randomized, double-blind, placebo-controlled study of revumenib in combination with intensive chemotherapy; topline results will inform the drug's efficacy and potential label expansion.
- 2042-12-18 · Patent_Expiry · REVUFORJ — Patent/Exclusivity Expiry — Expiry of patent or exclusivity protection for REVUFORJ, which could open the market to generic competition.
Risks & what to watch (4)›
Key risks
- Clinical trial uncertainty — Costs, timing, and outcomes of clinical trials are uncertain; company cannot estimate amounts needed for development or profitability [sec_mda · as of 2026-08-04].
- Operating losses and profitability — Significant operating losses since inception; profitability not achieved except for 2021 [sec_mda · as of 2026-02-26].
- Macroeconomic pressures — Inflation, supply chain constraints, and geopolitical tensions could increase costs and negatively affect operations [sec_mda · as of 2026-02-26].
- Debt obligations — Total debt of $350.0M as of 2026-06-30 may impose financial constraints [sec].
What to watch
- Phase 3 topline results for revumenib in combination with intensive chemotherapy, expected by 2031-01-01 [upcoming catalysts].
- Revenue growth from Revuforj and Niktimvo sales and collaboration milestones [sec_mda · as of 2026-02-26].
- Progress in expanding the pipeline through licensing and acquisition of additional therapeutics [sec_mda · as of 2026-02-26].
- Patent/exclusivity expiry for REVUFORJ on 2042-12-18 [upcoming catalysts].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Syndax Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Syndax Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
57.0 months
D/E 45.60 · 0% dilution
Lead: Approved
5 candidates
2 upcoming, next in ~1585d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
243
Total value held
$2.15B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,254,426 | $192.8M |
| vanguard capital management llc | 7,645,158 | $178.6M |
| goldman sachs group inc | 4,996,787 | $116.7M |
| state street corp | 4,430,076 | $103.5M |
| bank of america corp /de/ | 4,249,836 | $99.3M |
| deerfield management company, l.p. | 3,779,900 | $88.3M |
| woodline partners lp | 2,501,520 | $58.4M |
| kingdon capital management, l.l.c. | 2,500,000 | $58.4M |
| stempoint capital lp | 2,731,486 | $57.0M |
| geode capital management, llc | 2,157,058 | $50.4M |
Showing top 10 of 243 institutional holders of Syndax Pharmaceuticals Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 26.4%
- Days to cover
- 13.5
- Shares short
- 20,695,810
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Syndax Pharmaceuticals Inc?
Syndax Pharmaceuticals Inc (SNDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies, with two FDA-approved medicines—Revuforj (revumenib) and Niktimvo (axatilimab)—and a pipeline of additional candidates.
What is Syndax Pharmaceuticals Inc's lead drug candidate?
Syndax Pharmaceuticals Inc's most advanced tracked candidate is Axatilimab (Phase 2) for Chronic Graft-versus-host-disease; Idiopathic Pulmonary Fibrosis.
What is Syndax Pharmaceuticals Inc's next catalyst?
Syndax Pharmaceuticals Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten" — expected January 1, 2031.
Who is the CEO of Syndax Pharmaceuticals Inc?
Mr. Michael A. Metzger M.B.A. is the chief executive officer of Syndax Pharmaceuticals Inc (SNDX).
Where is Syndax Pharmaceuticals Inc headquartered?
Syndax Pharmaceuticals Inc (SNDX) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.